The '-omics' revolution and oesophageal adenocarcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 1, 2014, Pages 19-27

  Weaver, Jamie M J ^a   Ross Innes, Caryn S ^a   Fitzgerald, Rebecca C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; GEFITINIB; LAPATINIB; MICRORNA; PROTEIN P53; TRASTUZUMAB; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMICS; HELICOBACTER INFECTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTESTINE FLORA; MICROARRAY ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

ADENOCARCINOMA; ALGORITHMS; BARRETT ESOPHAGUS; DISEASE MANAGEMENT; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; GENOMICS; HUMANS; RISK FACTORS;

EID: 84891745767     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.150     Document Type: Review

References (108)

1. Pohl, H., Sirovich, B. & Welch, H. G. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19, 1468-1470 (2010)
2. van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074-2084 (2012)
3. Lagergren, J., Bergstrom, R., Lindgren, A. & Nyren, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999)
4. Chandrasoma, P., Wickramasinghe, K., Ma, Y. & DeMeester, T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus 20, 36-41 (2007)
5. Rudiger Siewert, J., Feith, M., Werner, M. & Stein, H. J. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann. Surg. 232, 353-361 (2000)
6. Demicco, E. G. et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-Type vs cardiac-Type mucosa-Associated adenocarcinoma. Mod. Pathol. 24, 1177-1190 (2011)
7. Derakhshan, M. H. et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 57, 298-305 (2008)
8. Lagergren, J. & Lagergren, P. Oesophageal cancer. BMJ 341, c6280 (2010)
9. Su, Z. et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barretts esophagus. Nat. Genet. 44, 1131-1136 (2012)
10. Kadri, S. R. et al. Acceptability and accuracy of a non-endoscopic screening test for Barretts oesophagus in primary care: cohort study. BMJ 341, c4372 (2010)
11. Cancer Prevention Trials Unit. BEST2. Cancer Prevention Trials Unit [online], http://www.cptu.org.uk/trials/BEST2.php (2013)
12. Hvid-Jensen, F., Pedersen, L., Drewes, A. M., Sorensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barretts esophagus. N. Engl. J. Med. 365, 1375-1383 (2011) Incidence of adenocarcinoma among patients with Barretts esophagus
13. Bhat, S. et al. Risk of malignant progression in Barretts esophagus patients: results from a large population-based study. J. Natl Cancer Inst. 103, 1049-1057 (2011)
14. Kerkhof, M. et al. Grading of dysplasia in Barretts oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50, 920-927 (2007)
15. Curvers, W. L. et al. Low-grade dysplasia in Barretts esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 105, 1523-1530 (2010)
16. Varghese, S., Lao-Sirieix, P. & Fitzgerald, R. C. Identification and clinical implementation of biomarkers for Barretts esophagus. Gastroenterology 142, 435-441 (2012)
17. Selaru, F. M. et al. Beyond field effect: analysis of shrunken centroids in normal esophageal epithelia detects concomitant esophageal adenocarcinoma. Bioinform. Biol. Insights 1, 127-136 (2007)
18. Prasad, G. A., Bansal, A., Sharma, P. & Wang, K. K. Predictors of progression in Barretts esophagus: current knowledge and future directions. Am. J. Gastroenterol. 105, 1490-1502 (2010)
19. Dunn, J. M. et al. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barretts oesophagus following photodynamic therapy. Br. J. Cancer 102, 1608-1617 (2010)
20. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012)
21. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423-425 (2012)
22. Duan, J., Zhang, J. G., Deng, H. W. & Wang, Y. P. Comparative studies of copy number variation detection methods for next-generation sequencing technologies. PLoS ONE 8, e59128 (2013)
23. Roychowdhury, S. et al. Personalized oncology through integrative high-Throughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011)
24. Akagi, T. et al. Chromosomal abnormalities and novel disease-related regions in progression from Barretts esophagus to esophageal adenocarcinoma. Int. J. Cancer 125, 2349-2359 (2009)
25. Walch, A. K. et al. Chromosomal imbalances in Barretts adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am. J. Pathol. 156, 555-566 (2000)
26. Lai, L. A. et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46, 532-542 (2007)
27. Paulson, T. G. et al. Chromosomal instability and copy number alterations in Barretts esophagus and esophageal adenocarcinoma. Clin. Cancer Res. 15, 3305-3314 (2009)
28. Brankley, S. M. et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barretts esophagus. J. Mol. Diagn. 8, 260-267 (2006)
29. Falk, G. W. et al. Fluorescence in situ hybridization of cytologic specimens from Barretts esophagus: a pilot feasibility study. Gastrointest. Endosc. 60, 280-284 (2004)
30. Rygiel, A. M. et al. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-Adenocarcinoma sequence of Barretts esophagus. Cancer Epidemiol. Biomarkers Prev. 17, 1380-1385 (2008)
31. Agrawal, N. et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2, 899-905 (2012)
32. Eads, C. A. et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61, 3410-3418 (2001)
33. Alvi, M. A. et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barretts esophagus. Clin. Cancer Res. 19, 878-888 (2013)
34. Agarwal, A. et al. Role of epigenetic alterations in the pathogenesis of Barretts esophagus and esophageal adenocarcinoma. Int. J. Clin. Exp. Pathol. 5, 382-396 (2012)
35. Wu, W. et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barretts esophagus and esophageal adenocarcinoma. Gastroenterology 144, 956-966 (2013)
36. Eads, C. A. et al. MethyLight: a high-Throughput assay to measure DNA methylation. Nucleic Acids Res. 28, E32 (2000)
37. Agarwal, R. et al. Epigenomic program of Barretts-Associated neoplastic progression reveals possible involvement of insulin signaling pathways. Endocr. Relat Cancer 19, L5-L9 (2012)
38. Schulmann, K. et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barretts-Associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148 (2005)
39. Group, E. S. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341, 1359-1362 (1993)
40. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227 (2012)
41. Yang, L. et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137, 588-597 (2009)
42. Fillon, S. A. et al. Novel device to sample the esophageal microbiome-The esophageal string test. PLoS ONE 7, e42938 (2012)
43. Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292-298 (2012)
44. Wang, J. et al. Differential gene expression in normal esophagus and Barretts esophagus. J. Gastroenterol. 44, 897-911 (2009)
45. Xu, Y. et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barretts esophagus and esophageal cancer. Cancer Res. 62, 3493-3497 (2002)
46. Peters, C. J. et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139, 1995-2004 (2010)
47. Kim, S. M. et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS ONE 5, e15074 (2010)
48. Kimchi, E. T. et al. Progression of Barretts metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 65, 3146-3154 (2005)
49. Nancarrow, D. J. et al. Whole genome expression array profiling highlights differences in mucosal defense genes in Barretts esophagus and esophageal adenocarcinoma. PLoS ONE 6, e22513 (2011)
50. Hao, Y. et al. Gene expression profiling reveals stromal genes expressed in common between Barretts esophagus and adenocarcinoma. Gastroenterology 131, 925-933 (2006)
51. Hammoud, Z. T. et al. Differential gene expression profiling of esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 137, 829-834 (2009)
52. Albrecht, B. et al. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barretts adenocarcinoma. J. Pathol. 203, 780-788 (2004)
53. Nancarrow, D. J. et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 68, 4163-4172 (2008)
54. Gu, J. et al. Genome-wide catalogue of chromosomal aberrations in barretts esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev. Res. (Phila) 3, 1176-1186 (2010)
55. Weaver, J. M. J. et al. OC-008 Defining the genetic landscape of oesopahgeal adenocarcinoma by next-generation sequencing. Gut 61 (Suppl. 2), A3-A4 (2012)
56. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013)
57. Dulak, A. M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383-4393 (2012)
58. Streppel, M. M. et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barretts esophagus. Oncogene http://dx.doi.org/10.1038/onc.2012.586.
59. Schneider, P. M. et al. Mutations of p53 in Barretts esophagus and Barretts cancer: a prospective study of ninety-eight cases. J. Thorac. Cardiovasc. Surg. 111, 323-331; discussion 331-333 (1996)
60. Barrett, M. T. et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 22, 106-109 (1999)
61. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011)
62. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012)
63. Zang, Z. J. et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012)
64. Wiegand, K. C. et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010)
65. Wertheimer, E. et al. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal. 24, 353-362 (2012)
66. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007)
67. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012)
68. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011)
69. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012)
70. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012)
71. International Cancer Genome Consortium. Esophageal cancer - esophageal adenocarcinoma. International Cancer Genome Consortium [online], http://icgc.org/icgc/cgp/72/508/70708 (2013)
72. National Cancer Institute. The Cancer Genome Atlas [online], http://cancergenome.nih.gov/(2013)
73. Ong, C. A. et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J. Clin. Oncol. 31, 1576-1582 (2013)
74. Schauer, M. et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin. Cancer Res. 16, 330-337 (2010)
75. Lagarde, S. M. et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann. Surg. Oncol. 15, 3459-3470 (2008)
76. Glas, A. M. et al. Converting a breast cancer microarray signature into a high-Throughput diagnostic test. BMC Genomics 7, 278 (2006)
77. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55-65 (2010)
78. Goh, X. Y. et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 60, 1317-1326 (2011)
79. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012)
80. Sharma, N. L. et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23, 35-47 (2013)
81. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012)
82. Alvarez, H. et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet. 7, e1001356 (2011)
83. Parameswaran, R. et al. Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers. Ann. Surg. Oncol. 20, 1970-1977 (2013)
84. Chau, I. et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann. Oncol. 20, 885-891 (2009)
85. Wang, K. et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219-1223 (2011)
86. Nagarajan, N. et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol. 13, R115 (2012)
87. Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J. Clin. Oncol. 31, 217-223 (2013)
88. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010)
89. Paterson, A. L. et al. Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J. Pathol. 230, 118-128 (2013)
90. Ferry, D. R. et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 13, 5869-5875 (2007)
91. Keld, R. R. & Ang, Y. S. Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? World J. Gastroenterol. 17, 2781-2790 (2011)
92. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010)
93. ISRCTN. Current Controlled Trials [online], http://www.controlled-Trials. com/ISRCTN49623344 (2013)
94. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00525200 (2012)
95. Banki, F. et al. Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch. Surg. 142, 533-538 (2007)
96. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013)
97. Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra68 (2012)
98. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008)
99. Leary, R. J. et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010)
100. Zhai, R. et al. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia 14, 29-33 (2012)
101. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008)
102. Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997-1006 (2008)
103. Bansal, A. et al. Feasibility of mcroRNAs as biomarkers for Barretts esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am. J. Gastroenterol. 106, 1055-1063 (2011)
104. Yang, H. et al. MicroRNA expression signatures in Barretts esophagus and esophageal adenocarcinoma. Clin. Cancer Res. 15, 5744-5752 (2009)
105. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012)
106. Diaz, L. A., Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012)
107. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012)
108. Mardis, E. R. The 1,000 genome, the 100,000 analysis? Genome Med. 2, 84 (2010)